Drug intelligence / Profile preview

MET-097iP

Development stage: Preclinical
Lead developer: Pfizer
Modality: Peptides
Administration: Oral

Overview

MET-097iP is an oral glucagon-like peptide 1 (GLP-1) receptor agonist being developed for the treatment of obesity and metabolic diseases. It was part of the pipeline of Metsera, a biopharmaceutical company that was acquired by Pfizer to bolster its presence in the high-demand weight loss market.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on MET-097iP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MET-097iP.

Explore the full profile